Cogent Biosciences Reports US FDA’s NDA Submission of Bezuclastinib for Gastrointestinal Stromal Tumors (GIST)

Why It Matters

The submission positions bezuclastinib as a potentially superior second‑line option for GIST, addressing an unmet need for patients refractory to imatinib and could reshape the market for tyrosine‑kinase inhibitors. Its accelerated regulatory pathway and expanded access may accelerate patient availability and bolster Cogent’s commercial prospects.

Key Takeaways

• FDA received NDA for bezuclastinib under RTOR program
• Phase III PEAK trial showed 50% PFS improvement
• ORR reached 46% versus 26% with sunitinib alone
• Mean treatment duration exceeded 19 months
• Phase II for exon 9 GIST; AdvSM NDA H1 2026

Pulse Analysis

The gastrointestinal stromal tumor (GIST) arena has long been dominated by imatinib, with sunitinib and regorafenib serving as subsequent lines of therapy. Yet a sizable subset of patients experience disease progression after imatinib, underscoring the need for more effective agents. Bezuclastinib, a next‑generation kinase inhibitor, targets multiple pathways implicated in GIST pathogenesis, offering a mechanistic rationale for combining it with sunitinib to overcome resistance mechanisms that limit monotherapy efficacy.

Data from the Phase III PEAK trial underscore this rationale. The combination delivered a median progression‑free survival of 16.5 months—nearly double that of sunitinib alone—while achieving a 46% objective response rate, a marked improvement over the 26% benchmark. Such outcomes not only extend the therapeutic window for patients but also suggest a potential shift in standard of care for those who have exhausted first‑line options. The durability of response, reflected in an average treatment duration exceeding 19 months, further highlights the regimen’s tolerability and sustained clinical benefit.

Cogent’s regulatory strategy leverages the FDA’s Real‑Time Oncology Review pathway to accelerate market entry, complemented by FDA‑aligned expanded access programs that provide early therapy to eligible patients. The forthcoming Phase II study targeting exon 9‑mutated GIST and the planned AdvSM NDA filing signal a broader ambition to position bezuclastinib across multiple rare oncology indications. If successful, these moves could enhance Cogent’s pipeline valuation, attract partnership interest, and ultimately expand treatment options for a patient population with limited alternatives.